Literature DB >> 26744598

A Review of Mathematical Models for Leukemia and Lymphoma.

Geoffrey Clapp1, Doron Levy2.   

Abstract

Recently, there has been significant activity in the mathematical community, aimed at developing quantitative tools for studying leukemia and lymphoma. Mathematical models have been applied to evaluate existing therapies and to suggest novel therapies. This article reviews the recent contributions of mathematical modeling to leukemia and lymphoma research. These developments suggest that mathematical modeling has great potential in this field. Collaboration between mathematicians, clinicians, and experimentalists can significantly improve leukemia and lymphoma therapy.

Entities:  

Year:  2014        PMID： 26744598      PMCID： PMC4698906          DOI： 10.1016/j.ddmod.2014.10.002

Source DB:  PubMed          Journal:  Drug Discov Today Dis Models        ISSN： 1740-6757


  32 in total

Review 1.  BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

Authors:  Xin An; Amit K Tiwari; Yibo Sun; Pei-Rong Ding; Charles R Ashby; Zhe-Sheng Chen
Journal:  Leuk Res       Date:  2010-10       Impact factor: 3.156

2.  Multistability in an age-structured model of hematopoiesis: Cyclical neutropenia.

Authors:  Jinzhi Lei; Michael C Mackey
Journal:  J Theor Biol       Date:  2010-11-19       Impact factor: 2.691

3.  Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.

Authors:  Jens Klaus; Doris Herrmann; Iris Breitkreutz; Ute Hegenbart; Uta Mazitschek; Gerlinde Egerer; Friedrich W Cremer; Ray M Lowenthal; Johannes Huesing; Stefan Fruehauf; Thomas Moehler; Anthony D Ho; Hartmut Goldschmidt
Journal:  Eur J Haematol       Date:  2006-09-28       Impact factor: 2.997

4.  Mathematical models of the fate of lymphoma B cells after antigen receptor ligation with specific antibodies.

Authors:  Tomás Alarcón; Radu Marches; Karen M Page
Journal:  J Theor Biol       Date:  2005-10-07       Impact factor: 2.691

5.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

6.  A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.

Authors:  John Carl Panetta; Yuri Yanishevski; Ching-Hon Pui; John T Sandlund; Jeffrey Rubnitz; Gaston K Rivera; Raul Ribeiro; William E Evans; Mary V Relling
Journal:  Cancer Chemother Pharmacol       Date:  2002-09-24       Impact factor: 3.333

7.  Drug resistance in cancer: principles of emergence and prevention.

Authors:  Natalia L Komarova; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-24       Impact factor: 11.205

8.  Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.

Authors:  John C Panetta; Alex Sparreboom; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  PLoS Comput Biol       Date:  2010-12-02       Impact factor: 4.475

9.  Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Authors:  Matthias Horn; Ingmar Glauche; Martin C Müller; Rüdiger Hehlmann; Andreas Hochhaus; Markus Loeffler; Ingo Roeder
Journal:  Blood       Date:  2012-11-21       Impact factor: 22.113

10.  Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells.

Authors:  J C Panetta; W E Evans; M H Cheok
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640
View more
  6 in total

1.  A study on the predictability of acute lymphoblastic leukaemia response to treatment using a hybrid oncosimulator.

Authors:  Eleftherios Ouzounoglou; Eleni Kolokotroni; Martin Stanulla; Georgios S Stamatakos
Journal:  Interface Focus       Date:  2017-12-15       Impact factor: 3.906

2.  Generalizations of the 'Linear Chain Trick': incorporating more flexible dwell time distributions into mean field ODE models.

Authors:  Paul J Hurtado; Adam S Kirosingh
Journal:  J Math Biol       Date:  2019-08-13       Impact factor: 2.259

3.  Study of cohabitation and interconnection effects on normal and leukaemic stem cells dynamics in acute myeloid leukaemia.

Authors:  Abdelhafid Zenati; Messaoud Chakir; Mohamed Tadjine
Journal:  IET Syst Biol       Date:  2018-12       Impact factor: 1.615

4.  An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.

Authors:  Michelle Przedborski; David Sharon; Severine Cathelin; Steven Chan; Mohammad Kohandel
Journal:  PLoS Comput Biol       Date:  2022-09-13       Impact factor: 4.779

5.  Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response.

Authors:  Yuji Okamoto; Mitsuhito Hirano; Kai Morino; Masashi K Kajita; Shinji Nakaoka; Mayuko Tsuda; Kei-Ji Sugimoto; Shigehisa Tamaki; Junichi Hisatake; Hisayuki Yokoyama; Tadahiko Igarashi; Atsushi Shinagawa; Takeaki Sugawara; Satoru Hara; Kazuhisa Fujikawa; Seiichi Shimizu; Toshiaki Yujiri; Hisashi Wakita; Kaichi Nishiwaki; Arinobu Tojo; Kazuyuki Aihara
Journal:  NPJ Syst Biol Appl       Date:  2022-10-13

6.  Spatial structure governs the mode of tumour evolution.

Authors:  Robert Noble; Dominik Burri; Cécile Le Sueur; Jeanne Lemant; Yannick Viossat; Jakob Nikolas Kather; Niko Beerenwinkel
Journal:  Nat Ecol Evol       Date:  2021-12-23       Impact factor: 19.100
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.